Rune Labs, Inc., a San Francisco, CA-based developer of software that enables the development and delivery of the next wave of neuroscience therapeutics, secured $5m in seed funding.
The round, which brought total funding raised to date to $7.3m, was led by DigiTx Partners, with participation from TruVenturo, Moment Ventures, Loup Ventures and Sabbatical Ventures.
The company will use the funds to continue to invest in R&D and to develop additional products.
Led by Brian Pepin, founder and CEO, Rune Labs partners with med-tech and pharma companies to label, organize, and analyze brain data. The company is particularly focused on neuromodulation therapies such as Deep Brain Stimulation (DBS) and Transcranial Magnetic Stimulation (TMS).
With its platform, brain data can be sequenced both longitudinally for a single patient and across multiple patients, studies, and centers to be analyzed with machine learning tools.